Prevention of Postoperative Venous Thrombosis: A Randomized Trial Comparing Unfractionated Heparin with Low Molecular Weight Heparin in Patients Undergoing Total Hip Replacement

Summary

A double blind randomized trial comparing subcutaneous enoxaparin (40 mg once daily) with standard unfractionated calcium heparin administered at a dose of 5,000 units every 8 hours in patients undergoing elective hip replacement has been performed. Treatment regimens began 12 hours preoperatively with enoxaparin, 2 hours preoperatively with standard unfractionated calcium heparin, and were continued for 15 days or until discharge. Venography was performed in all patients. Two hundred thirty-seven patients were included in the study: 113 received unfractionated heparin and 124 received enoxaparin. The incidence of proximal deep vein thrombosis was reduced from 18.5% in the unfractionated heparin group to 7.5% in the enoxaparin group (p = 0.014), and the incidence of total deep vein thrombosis was similarly reduced from 25% to 12.5% (p = 0.03). There were two major bleeding episodes and one minor bleed in the enoxaparin group compared to two minor bleeds in the unfractionated heparin group. Patients who received enoxaparin required fewer red blood cell transfusions and had a significantly higher hemoglobin on postoperative days 3 and 4. Thus prophylaxis with enoxaparin, 40 mg once daily, is simple, safe and more effective than standard low dose unfractionated heparin in preventing deep vein thrombosis in patients undergoing elective hip replacement.

Key words

Low molecular weight heparin - Postoperative thrombosis - Total hip replacement

• References

• 1 Turpie A GG, Levine MN, Hirsh J, Carter CJ, Jay RM, Powers PJ, Andrew M, Hull R, Gent M. A randomized controlled trial of a low molecular-weight Hqparin (Enoxaparin) to prevent deep vein thrombosis in patients undergoing elective hip surgery. N Engl J Med 1986; 315: 925-929
• 2 Planes A, Vochelle N, Ferru J, Przyrowski D, Clerc J, Fagola M, Planes M. Enoxaparin, Low Molecular Weight Heparin: Its use in the prevention of deep venous thrombosis following total hip replacement. Haemostasis 1986; 16: 152-158
• 3 Planes A, Vochelle N, Mansat C. Prevention of deep vein thrombosis after total hip replacement by Enoxaparin. One daily injection of 40 mg versus two daily injections of 20 mg. Thromb Haemostas 1987 58: Abstract
• 4 Morris GK, Henry A PJ, Preston BJ. Prevention of deep-vein thrombosis by low-dose heparin in patients undergoing total hip replacement. Lancet 1974; 2: 797-799
• 5 Mannucci PM, Citterio LE, Panajotopoulos N. Low dose heparin and deep vein thrombosis after total hip replacement. Thromb Haemostas 1976; 36: 157-164
• 6 Venous Thrombosis Clinical Study Group. Small doses of subcutaneous sodium heparin in the prevention of deep vein thrombosis after elective hip operations. Br J Surg 1975; 62: 348-350
• 7 Moskovitz PA, Ellenberg SS, Feffer HL, Kenmore PI, Neviaser RJ, Rubin BE, Varma VM. Low dose heparin for prevention of venous thromboembolism in total hip arthroplasty and surgical repair of hip fractures. J Bone Joint Surg (AM) 1978; 60: 1065-1070
• 8 Dechavanne M, Saudin F, Viala JJ, Kher A, Bertrix L, De Mourgues G. Prevention des thromboses veineuses: succes de l’héparine à fortes doses lors des coxarthroses. Nouv Presse Med 1974; 3: 1317-1319
• 9 Gallus AS, Hirsh J, Tuttle RJ, Trebilcock R, O’Brien ST, Carroll JJ, Minden JH, Hudeckl SM. Small subcutaneous doses of heparin in prevention of venous thrombosis. N Engl J Med 1973; 288: 545-551
• 10 Hampson WG, Harris FC, Keith LucasH, Roberts PH, McCall IW, Jackson PC, Powell NL, Staddon GE. Failure of Low-dose heparin to prevent deep vein thrombosis after hip-replacement arthroplasty. Lancet 1974; 2: 795-797
• 11 Hume M, Kuriakose TX, Zuch L, Turner RH. I-fibrinogen and the prevention of venous thrombosis. Arch Surg 1973; 107: 803-806
• 12 Carter CJ, Kelton JG, Hirsh J, Cerskus A, Santos AV, Gent M. The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits. Blood 1982; 59: 1239-1245
• 13 Zachrisson BE, Jansen HJ. Phlebographic signs in fresh postoperative venous thrombosis of the lower extremity. Acta Radiol (Diagn) (Stockh) 1973; 14: 82-96
• 14 Hull R, Hirsh J, Jay R, Carter C, England CY, Gent M, Turpie A GG, McLoughlin P, Dodd M, Thomas D, Rascob G, Ockelford P. Different intensities of oral anticoagulant Therapy in the treatment of proximal vein thrombosis. N Engl J Med 1982; 307: 1676-1681
• 15 Hirsh J, Genton E, Hull R. Venous Thromboembolism. Grune and Stratton 1981; 114-115
• 16 Bergquist D. Post Operative Thrombo-embolism. Springer Verlag; Berlin: 1983: 16-22
• 17 Francis CW, Marder VJ, Evarts CM, Yaukoolbodi S. Two-step warfarin therapy. Prevention of post-operative venous thrombosis without excessive bleeding. JAMA 1983; 249: 374-378
• 18 Paiment GD, Bell D, Weissinger SJ, Harris WH. New advances in the prevention, diagnosis and cost effectiveness of venous thromboembolic disease in patients with total hip replacement. In: The Hip-Proceedings of the Hip Society Mosby: 1986: 94-119
• 19 Leyvraz PF, Richard J, Backmann F, van Melle G, Treyvaud JM, Livig JJ, Candarjis G. Adjusted versus fixed dose subcutaneous Heparin in the prevention of deep vein thrombosis after total hip replacement. N Engl J Med 1983; 309: 954-958
• 20 Aiach M, Michaud A, Balian JL, Lefebvre M, Woler M, Fourtillan J. A new low molecular weight heparin derivative: in vitro and in vivo study. Thromb Res 1983; 31: 611-621
• 21 Vinazzer H, Woler M. A New Low Molecular Weight Heparin Fragment (PK 10169). In vitro and in vivo studies. Haemostasis 1986; 16: 106-115
• 22 Dawes J, Bara L, Billaud E, Samama M. Relationship between biological activity and concentration of a low molecular weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration. Haemostasis 1986; 16: 116-122
• 23 Fareed J, Walenga JM, Hoppenstead DA, Martin EmanueleR. Laboratory Studies on the intravenous and subcutaneous administration of PK 10169 in man. Haemostasis 1986; 16: 123-138
• 24 Bara L, Le Roux Y, Woler M, Chauliac F, Frydman A, Samama M. Pharmacokinetics of Enoxaparin after single subcutaneous administration of increasing doses (20 up to 80 mg) to healthy volunteers. Thromb Hemostas 1987; 58: 117 (417, Abstr)
• 25 Francis CW, Marder VJ, Evarts CM. Lower risk of thromboembolic disease after total hip replacement with non cemented than with cemented prostheses. Lancet 1986; 1: 769-771